Navigation Links
Three Organizations Receive CEO Cancer Gold Standard(TM) Accreditation
Date:10/11/2007

Duke Medicine, University of North Dakota and Valeant Pharmaceuticals join

workplace wellness leadership effort

CARY, N.C., Oct. 11 /PRNewswire-USNewswire/ -- Today, three organizations, Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, were accredited with the CEO Cancer Gold Standard(TM), certifying their commitment to the health of their employees and their families by agreeing to meet an exceptionally high standard of cancer prevention, screening and care guidelines. In doing so, they join with thirteen other organizations that have answered former President George H.W. Bush's call for business leaders to be "bold and venturesome" in their efforts in preventing cancer in the workplace and in their leadership in the overall fight against cancer.

William C. Weldon, chairman and chief executive officer of Johnson & Johnson, chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with leading health professionals. "Adopting the Gold Standard is a tribute to the value these CEOs place on their employees and to the extraordinary leadership they provide their organizations and to all of those committed to winning the battle against cancer."

The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.

Earlier this year, the President's Cancer Panel report, "Promoting Healthy Lifestyles: Policy, Program, and Personal Recommendations for Reducing Cancer Risk," identified the CEO Cancer Gold Standard(TM) as an initiative that is helping reverse negative, unhealthy lifestyle trends and creating hope in the fight against cancer for America's workers and their families.

In addition to Duke Medicine, The University of North Dakota and Valeant Pharmaceuticals, thirteen other companies have received the CEO Cancer Gold Standard(TM) accreditation from the CEO Roundtable on Cancer. They are: American Cancer Society (national headquarters), American Legacy Foundation, AstraZeneca, Edelman, Enzon Pharmaceuticals, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, Quintiles Transnational and SAS Institute.

About the CEO Roundtable on Cancer

The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives, led by Robert A. Ingram, then the CEO of Glaxo Wellcome, now GlaxoSmithKline, to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded with the CEO Cancer Gold Standard, and have since collaborated with the American Cancer Society to encourage its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please call 866-526-7830 or visit http://www.CancerGoldStandard.org.

For more information:

CEO Roundtable on Cancer

John Dornan, Executive Director

P: 919-531-0966

E: John.Dornan@CEORoundtableOnCancer.org

To read the President's Cancer Panel report, please go to: http://deainfo.nci.nih.gov/advisory/pcp/pcp07rpt/pcp07rpt.pdf

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE CEO Roundtable on Cancer
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Nobel Prize for Medicine shared by Three scientists
3. Biotechnology industry expected to grow into a three billion dollar industry by 2002
4. Baltimore doctors perform three simultaneous kidney transplants
5. FDA gives “black box warning” against three asthma drus
6. Three Tropical Parasites Genetic Code Unravelled
7. The Future Pattern Of Weight Gain Is Laid As Early As Three Years Of Age
8. Smoking Increases The Risk Of Heart Disease By Three Times
9. Three Sisters Have One Baby and Make History
10. Three In One Ultrasound Probe For 3-D Imaging Of Heart And Tissue Destruction Developed
11. Three More Bird Flu Cases Reported By China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 One of Australia,s ... the formation of a new biotechnology company, Noxopharm Limited [ABN 50 ... an IPO and to list on the ASX. Noxopharm ... ready to enter a Phase 1 clinical study later this year. ... address one of the biggest problems facing cancer patients - the ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: